Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364150 | 1.00 | GAA (0.50) | GAAMAPTSMN1; SMN2RAB9ALMNA | |
| SCHEMBL31247827 | 0.84 | SMN1; SMN2 (0.44) | GAASMN1; SMN2RAB9ALMNAHTT | |
| SCHEMBL28851379 | 0.81 | GAA (0.46) | GAAMAPTHTTBRD4HDAC1 | |
| SCHEMBL27956815 | 0.81 | CYP3A4 (0.54) | GAAMAPTSMN1; SMN2RAB9ALMNA | |
| SCHEMBL27407526 | 0.79 | BRD4 (0.46) | GAAMAPTLMNAHTTMEN1 | |
| SCHEMBL3806937 | 0.78 | SMN1; SMN2 (0.48) | GAAMAPTSMN1; SMN2RAB9ALMNA | |
| SCHEMBL30047375 | 0.78 | ALDH1A1 (0.56) | GAAMAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL27217167 | 0.78 | BRD4 (0.45) | GAAMAPTLMNAHTTMEN1 | |
| SCHEMBL27385894 | 0.78 | CYP11B1 (0.53) | GAAMAPTSMN1; SMN2RAB9ALMNA | |
| SCHEMBL7465706 | 0.78 | ALDH1A1 (0.56) | GAAMAPTSMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104136434-B | FGF receptor (FGFR) agonist dimeric compounds thing, its preparation method and its therapeutic use | 赛诺菲 | 2016-07-06 | — | — | CN | disclosed |
| US-20140348850-A1 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN | JOSLIN DIABETES CENTER | 2014-11-27 | — | — | US | disclosed |
| US-8658685-B2 | Methods for treatment of kallikrein-related disorders | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2542525-A1 | CATIONIC 6-AMINOINDOLINES, DYEING COMPOSITIONS CONTAINING THEM, PROCESSES AND USES THEREOF | L'Oréal (FR) | 2013-01-09 | — | — | EP | disclosed |
| EP-2509977-A1 | NOVEL CATIONIC 4-AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | L'Oréal (FR) | 2012-10-17 | — | — | EP | disclosed |
| US-8258170-B2 | Inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110318359-A1 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN | JOSLIN DIABETES CENTER | 2011-12-29 | — | — | US | disclosed |
| US-20110301215-A1 | INHIBITORS OF PLASMA KALLIKREIN | Activesite Phamaceuticals, Inc. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011107501-A1 | CATIONIC 6-AMINOINDOLINES, DYEING COMPOSITIONS CONTAINING THEM, PROCESSES AND USES THEREOF | L'OREAL (FR) | 2011-09-09 | — | — | WO | disclosed |
| US-7977380-B2 | Inhibitors of plasma kallikrein | Activesite Pharmaceticals, Inc. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110065757-A1 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS | JOSKIN DIABETES CENTER (US) | 2011-03-17 | — | — | US | disclosed |
| US-20100130563-A1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7625944-B2 | Inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080038276-A1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065757-A1 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS | KLKB1, SERPINE1, KLK1 | GAA 349/4885MAPT 192/4885SMN1; SMN2 587/4885 |
| US-20080038276-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | GAA 842/4885MAPT 1928/4885SMN1; SMN2 3269/4885 |
| US-20100130563-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | GAA 842/4885MAPT 1928/4885SMN1; SMN2 3269/4885 |
| US-20140348850-A1 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK2 | GAA 1103/4885MAPT 3433/4885SMN1; SMN2 4390/4885 |
| US-20110318359-A1 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK2 | GAA 1103/4885MAPT 3433/4885SMN1; SMN2 4390/4885 |
| US-20110301215-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | GAA 842/4885MAPT 1928/4885SMN1; SMN2 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.